Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the efficacy of Vorasidenib for the treatment of brain tumours.
In the United Kingdom, medicines need to have a licence before they can be marketed, and these are granted by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA has not issued a scientific opinion for Vorasidenib. Should an application for Vorasidenib be received, the MHRA will consider this accordingly.